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ABSTRACT
Context: Diclofenac (DIC) is an NSAID and consumption of this drug creates side effects such as liver
injury. Gallic acid (GA), a natural component of many plants, is used as an antioxidant agent.
Objective: This study assesses the hepatoprotective effects of GA in the rat model of DIC-induced
liver toxicity.
Materials and methods: In this research, the male Wistar rats were separated into five groups (n¼ 6).
Group 1, control, received normal saline (1mL/kg bw, i.p.); Group 2 received DIC-only (50mg/kg bw, i.p.);
Groups 3, received DIC (50mg/kg bw, i.p.) plus silymarin (100mg/kg bw, po), groups 4 and 5 received
DIC (50mg/kg bw, i.p.) plus GA (50 and 100mg/kg, po, respectively).
Results: The data demonstrated that the liver levels of the GSH, GPx, SOD, and CAT significantly reduced
and the levels of the serum protein carbonyl, AST, ALP, ALT, total bilirubin, MDA, serum IL-1b, and the
liver IL-1b gene expression were remarkably increased in the second group compared to control group.
On the other hand, treatment with GA led to a significant elevation in GSH, GPx, SOD, CAT, and a signifi-
cant decrease in protein carbonyl, AST, ALP, ALT, total bilirubin, MDA, serum IL-1b, and gene expression
of IL-1b in comparison with the second group. Histological changes were also ameliorated by GA oral
administration.
Discussion and Conclusions: The data show that the oral administration of GA could alleviate the nox-
ious effects of DIC on the antioxidant defense system and liver tissue.
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The liver is a vital organ that has various roles in the body,
including the production of proteins, manufacturing triglycerides
and cholesterol, glycogen synthesis, and bile creation. The liver is
involved in metabolising various toxins, including chemicals,
drugs, and natural substances (Jameson 2018). Nonsteroidal anti-
inflammatory drugs (NSAIDs) are commonly applied for reliev-
ing inflammatory illnesses and pain. Therapeutic doses of
NSAIDs generally produce only mild side effects, however, over-
doses of these drugs can produce severe toxicity. The majority of
NSAIDs inhibit COX enzymes and consequently change prosta-
glandin production, and as a result, liver and kidney cells are
exposed to injury (Alabi and Akomolafe 2020; Besen et al. 2009;
Chandrasekharan et al. 2002). Diclofenac (DIC) is an NSAID
with analgesic, anti-inflammatory, antipyretic, and antinocicep-
tive attributes (Mazumdar et al. 2006). It is widely used in the
treatment of rheumatoid arthritis pain. In spite of the therapeutic
profits of DIC, it has serious severe side effects, including gastro-
intestinal injury and damage to hepatic, renal, lungs, and cardiac
tissues (Harirforoosh et al. 2016; Tomic et al. 2008). Production
of reactive oxygen species (ROS) and reactive metabolites has
been considered as the major cause of DIC-induced hepatotox-
icity. Cytochrome P450-dependent oxidation of DIC creates 2,5-
quinone imines and 40,5-hydroxy-diclofenac (Al-dossari et al.
2020). These factors can cause covalent alteration of proteins and
conjugate with glutathione (GSH) to produce adducts of GSH
(Tang 2003). The metabolites of DIC can elevate the production
of ROS via the induction of redox imbalance and mitochondrial
dysfunction (Moreno-Sanchez et al. 1999). Hepatocyte damage
by DIC’s generation of extra ROS has been well documented
(Elgebaly et al. 2018; Mahmoud et al. 2017). Thus, it is reason-
able to assume that high levels of antioxidants would be required
to ameliorate DIC-induced toxicity.
Gallic acid (GA) is a naturally occurring compound of many
plants that is used in the food, cosmetics, and drug industries.
GA is widely found throughout the plant kingdom and is a well-
known antioxidant (Kim 2007; Priscilla and Prince 2009), fur-
thermore, there exists a large volume of scientific evidence docu-
menting its antibacterial, antiviral, antifungal, anticancer, and
antioxidant activities (Nabavi et al. 2013; Omobowale et al.
2018). Nevertheless, based on our review of the literature, the
effects of GA on DIC-induced liver toxicity and oxidative stress
have not been investigated. In this study, we evaluated the
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2-Thiobarbituric acid (TBA), sodium acetate, and H2O2 were
procured from Merck (Darmstadt, Germany). Greiss reagent, gal-
lic acid, 5,5-dithiobis-2-nitrobenzoic acid, nitro blue tetrazolium,
and TPTZ (2,4,6-tripyridyl-s-triazine), and 2,4-dinitrophenylhy-
drazine were obtained from Sigma-Aldrich Company (St. Louis,
MO, USA). SYBRR Green Real Time-PCR Master Mix was pur-
chased from the Qiagen Co. (Dusseldorf, Germany). The IL-1b
kit used was procured from the Bioassay Technology
Laboratories (BT Lab) in China. Total bilirubin, ALP (alkaline
phosphatase), ALT (alanine aminotransferase) and AST (aspar-
tate aminotransferase) kits were provided by Pars Azmoon Co.
(Tehran, Iran).
Animals
Thirty male Wistar rats weighting 200 ± 20 g (6–8-week old)
obtained from the Tehran Pasteur Institute (Tehran, Iran) were
used. The rats were kept in standard laboratory conditions,
including 25 C ambient temperature, 50% relative humidity, and
a 12 h dark/light cycle, and were allowed free access to water and
standard diet. The whole protocol of the research was approved
by Shahrekord University of Medical Sciences Ethics Committee,
Shahrekord, Iran (Ethic number, IR. SKUMS. REC. 1394. 146).
Study design
The thirty male Wistar rats were randomly placed into 5 groups
(n¼ 6). Group 1 was the control group receiving normal saline
(1mL/kg body weight (bw), i.p.) and 1mL distilled water as the
solvent of GA by gavage at an interval of 1 h for 5 days to pro-
vide an equal shock in the control group as opposed to other
groups. Group 2 received DIC only (50mg/kg bw, i.p.) and 1mL
distilled water (solvent of GA, po) at an interval of 1 h for 5 days
(Aydin et al. 2003; Peter et al. 2017). Group 3 received DIC
(50mg/kg bw, i.p.) and 1mL of silymarin (100mg/kg bw, po) at
an interval of 1 h for 5 days (Peter et al. 2017; Heidarian and
Nouri 2019). Groups 4 and 5 received DIC (50mg/kg bw, i.p.)
and 1mL of GA (50 and 100mg/kg, po, respectively) at an inter-
val of 1 h for 5 days (Jadon et al. 2007; Padma et al. 2011). At
the end of the study, rats were fasted for 12 h and then sacrificed
under mild anaesthesia. Whole blood specimens were collected
by cardiac puncture method to gain plasma and serum. In add-
ition, liver tissues were separated for obtaining liver SOD, CAT
activities, lipid peroxidation (LPO), IL-1b gene expression, and
histological studies.
Determination of serum biochemical parameters
Total bilirubin, ALP, ALT, and AST liver enzymes were deter-
mined using an auto-analyzer system (BT3000, Rome, Italy).
Determination of plasma antioxidant capacity
Plasma antioxidant capacity calculated by ferric reducing/antioxi-
dant power (FRAP) method as described previously (Nouri
et al. 2019).
Determination of nitrite content
Determining of nitrite content was done by using Greiss reagent
as described previously (Heidarian and Nouri 2019).
Determination of lipid peroxidation (LPO) and serum protein
carbonyl (PC)
Serum and liver MDA levels were determined by the TBA
method as previously described by Heidarian and Soofiniya
(2011). The serum PC was assessed using Reznick and Packer
(1994) protocol at 360 nm with 6M guanidine hydrochloride.
The results were demonstrated in nmol dinitrophenyl hydrazine
(DNPH)/mg protein.
Determination of tissue CAT and SOD activities
The liver CAT activity of experimental groups was measured as
described previously (Heidarian et al. 2014). The activity of liver
SOD was evaluated using the inhibition of the nitro blue tetrazo-
lium (NBT) photochemical reaction at 560 nm (Flohe 1984). All
total protein samples were assessed using the method of
Bradford (1976). Data were described as U/mg protein.
Determination of tissue GSH levels
Reduced GSH content was assayed according to the Ellman
(1959) method. The GSH reacts with 5,5-dithiobis-2-nitrobenzoic
acid and the absorbance spectra have a peak value at 410 nm.
The data were demonstrated as lmol/g tissue.
Tissue GPx activity
GPx activity was evaluated by determining the reduction in GSH
content after incubating the sample in the presence of H2O2 and
NaN3 (Hafeman et al. 1974).
Determination of serum IL-1b
The serum level of IL-1b was assessed using the ELISA assay kit
according to the manufacturer’s instructions. Data were reported
as pg/mL.
Real-time RT-PCR analysis
The liver mRNA was extracted using the BIOZOL kit reagent
(Bioer, China) according to the instructions. The quality and
quantity of total RNA were assessed by reading absorbance at
260/280 nm using a spectrophotometer (Nanodrop2000, Thermo,
USA). cDNA measurement was accomplished using a
PrimeScriptTM reagent kit (Takara Bio Inc. Japan) in accordance
with the manufacturer’s instructions. Then, cDNA was amplified
according to RT-qPCR using SYBRVR Green PCR Master Mix
in the presence of IL-1b primer (forward sequence 50-
CAACAAAAATGCCTCGTGCTG-30 and reverse sequence
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50-TCGTTGCTTGTCTCTCCTTGTA-30) and b-actin primer
(forward sequence 50-CGCAAATTACCCACTCCCGAC-30 and
reverse sequence 50-GTAACCTCCCGTTCAGACCAC-30). The
primers were designed by Oligo 7.0 software and they were con-
firmed by Blast Nucleotide (NCBI). PCR carried out in primary
denaturation at 95 C for 10min. RT-q PCR was performed in
40 cycles (including secondary denaturation at 95 C for 15 sec,
annealing at 60 C for 20 sec, and extension at 72 C for 25 sec).
b-Actin gene was used as an internal control gene to control the
expression of mRNA. Further, the DDCT method was used for
the analysis of gene expression.
Histopathological study
After sacrificing the rats, their livers were fixed in 10% formal-
dehyde solution and were dissected by a microtome (AMR 400,
Amos Scientific, Australia) in 5lm slices of tissue, and after
paraffin embedding, stained with haematoxylin, and eosin
(H&E) (Carleton et al. 1980). The liver histopathological exami-
nations, routine haematoxylin and eosin (H&E) staining, were
performed. An optical microscope (Nikon Eclipse E400 micro-
scope with a digital camera, USA) was used to evaluate tis-
sue changes.
Statistical analysis
One-way analysis of variance (ANOVA) was used for data ana-
lysis using SPSS software (Statistical Package for the Social
Sciences, version 20.0, SPSS Inc, Chicago, IL). All data were
expressed as mean ± SD. The mean values of the groups were
compared using the Tukey’s post hoc test. p< 0.05 was consid-
ered a significance level.
Results
Effect of gallic acid on serum ALT, AST, ALP and
total bilirubin
The results indicated that injection of DIC for 5 days led to a sig-
nificant increase (p< 0.05) in total bilirubin, AST, ALP, and ALT
in rats received DIC-alone compared to the control group (Table
1). Treatment with GA at doses of 50 and 100mg/kg reduced the
serum levels of above mentioned parameters when compared with
the group received DIC-alone. Total bilirubin, AST, ALP, and
ALT levels decreased significantly in the rats received 100mg/kg
GA (p< 0.05), compared to those received 50mg/kg GA.
Effect of gallic acid on plasma antioxidant capacity, nitrite
content and MDA levels
Table 2 shows that injection of DIC in the DIC-alone treated
group caused a remarkable decrease (p< 0.05) in plasma antioxi-
dant capacity and a noticeable increased in nitrite level, liver
MDA, and serum MDA contents compared to the control animals
(group 1). On the other hand, treatment with GA at doses of 50
and 100mg/kg caused a noticeable raised (p< 0.05) in plasma
antioxidant capacity and a noticeable decreased (p< 0.05) in
nitrite content, serum MDA and liver MDA levels compared to
the DIC-alone treated group. A significant change (p< 0.05) in
plasma antioxidant capacity, nitrite content, serum MDA and liver
MDA between rats received GA in doses of 50 and 100mg/kg
was found.
Effect of gallic acid on serum protein carbonyl (PC)
Serum PC content increased considerably (p< 0.05) in the rats
injected with DIC, compared to the control group (Table 2).
However, the serum PC level in rats administrated with two dif-
ferent doses of GA (50 and 100mg/kg) and a single dose of
Table 1. Effect of gallic acid on serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and
total bilirubin.
Parameters Group 1 Group 2 Group 3 Group 4 Group 5
ALT (U/L) 65.2 ± 5.1 136.8 ± 11.7a 66.2 ± 9.8b 96.1 ± 8.1abc 68.9 ± 11.1bd
AST (U/L) 138.5 ± 16.7 286.7 ± 17.5a 144.6 ± 15.7b 198.7 ± 14.6abc 143.4 ± 13.7bd
ALP (U/L) 180.2 ± 19.5 458.6 ± 45.1a 189.9 ± 22.1b 281.3 ± 34.2abc 186.3 ± 21.2bd
Total bilirubin (mg/dl) 0.84 ± 0.08 2.32 ± 0.42a 0.82 ± 0.12b 1.42 ± 0.25abc 0.91 ± 0.13bd
Data are expressed as mean ± SD (n¼ 6) and analysed by one-way ANOVA followed by Tukey post hoc test. Group 1: control group; Group
2: diclofenac-alone treated group; Group 3: treated by diclofenac plus silymarin (100mg/kg p.o.); Groups 4 and 5 were treated by diclofe-
nac plus gallic acid (50, 100mg/kg p.o. respectively).
ap< 0.05 versus control group (Group 1),
bp< 0.05 versus diclofenac-alone treated group (Group 2),
cp< 0.05 versus group treated with silymarin (Group 3),
dp< 0.05 versus group treated with gallic acid at dose of 50mg/kg (Group 4).
Table 2. Effect of gallic acid on ferric reducing/antioxidant power (FRAP), malondialdehyde (MDA), and protein carbonyl (PC) levels.
Parameters Group 1 Group2 Group 3 Group 4 Group 5
Plasma FRAP (lM) 661.2 ± 60.1 332.1 ± 33.4a 671.2 ± 51.6b 518.1 ± 41.2abc 658.8 ± 49.6bd
Serum MDA (nmol/L) 9.12 ± 0.62 20.14 ± 2.11a 9.42 ± 1.06b 14.61 ± 1.69abc 9.58 ± 1.32bd
Liver MDA (nmol/mg protein) 1.38 ± 0.21 5.46 ± 1.05a 1.42 ± 0.29b 2.98 ± 0.63abc 1.51 ± 0.38bd
Serum PC (nmolNADPH/mg protein) 5.11 ± 0.71 12.61 ± 1.12a 4.98 ± 0.89b 8.28 ± 1.29abc 5.23 ± 0.91bd
Data are expressed as mean ± SD (n¼ 6) and analysed by one-way ANOVA followed by Tukey post hoc test. Group 1: control group; Group 2: diclofenac-alone
treated group; Group 3: treated by diclofenac plus silymarin (100mg/kg p.o.); Groups 4 and 5 were treated by diclofenac plus gallic acid (50, 100mg/kg p.o.
respectively).
ap< 0.05 versus control group (Group 1),
bp< 0.05 versus diclofenac-alone treated group (Group 2),
cp< 0.05 versus group treated with silymarin (Group 3),
dp< 0.05 versus group treated with gallic acid at dose of 50mg/kg (Group 4).
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silymarin (100mg/kg) significantly decreased (p< 0.05) com-
pared to the rats injected with DIC-only. The serum PC level
was remarkable (p< 0.05) between the fourth and fifth groups
(rats administered with 50 and 100mg/kg bw GA, respectively).
Effect of gallic acid on CAT, SOD, GPx activities and
GSH level
Table 3 shows that the injection of DIC led to a remarkably
decrease (p< 0.05) in hepatic CAT and SOD activities in the
DIC-alone treated group relative to the control animals.
However, treatment with GA at doses of 50 and 100mg/kg
remarkably elevated liver SOD and CAT activities relative to the
DIC-alone treated group. Table 3 also indicated a noticeable
(p< 0.05) decline in liver GPx activity in the DIC-alone treated
group compared to the control animals. However, the adminis-
tration of GA at doses of 50 and 100mg/kg caused a remarkable
increase (p< 0.05) in liver GPx activity in comparison with the
DIC-alone injected group. Also, injection of DIC in the DIC-
alone injected group caused a noticeable decline (p< 0.05) in
liver GSH compared to the control group (Table3). However, in
groups treated with doses of 50 and 100mg/kg GA (groups 4
and 5), liver GSH noticeably elevated (p< 0.05) compared to the
second group (DIC-alone injected group).
Effect of gallic acid on serum level and gene expression of
IL-1b
Figure 1 indicated IL-1b fold change expression in the studied
groups. The results of this study indicated that the expression of
the IL-1b gene in the DIC-only treated group increased in
comparison with the control group (p< 0.05). However, in the
treated groups with GA in doses of 50, and 100mg/kg the
expression of this gene reduced noticeably (p< 0.05) compared
to the DIC-alone treated group. GA was able to reduce the IL-1b
level at a dose of 100mg/kg more than the other dose. Also, the
injection of DIC in the DIC-alone treated group resulted in a
significant increase (p< 0.05) in the serum level of IL-1b relative
to the control group (Figure 1). However, in groups treated with
GA at doses of 50, and 100mg/kg the serum level of this protein
significantly (p< 0.05) decreased compared to the DIC-alone
treated group. There was no significant difference between the
group treated with 100mg/kg GA and control group.
Histopathological findings
Figure 2 indicated the representative histopathological studies in
the experimental groups. Histology showed the normal morph-
ology of the hepatocytes in the control group (Figure 2(A)).
Injection of DIC in the DIC-alone treated group led to the infil-
tration of lymphocyte cells in comparison with the control group
(Figure 2(B)). Also, DIC-injected rats supplemented with sily-
marin showed decreased inflammatory cell infiltration relative to
the DIC-alone treated group (Figure 2(C)). Liver degeneration
and lymphocytic cell infiltration were significantly reduced in
groups treated with GA at doses of 50 and 100mg/kg compared
to the DIC-alone treated group (Figure 2(D,E)).
Discussion
Some drug metabolism and detoxification are accompanied by
GSH conjugation that results in decrease antioxidant status and
Table 3. Effect of gallic acid on catalase (CAT) activity, superoxide dismutase (SOD) activity, glutathione peroxidase (GPx) activity and
Intracellular glutathione (GSH) level.
Parameters Group 1 Group2 Group 3 Group 4 Group 5
CAT (U/mg protein) 176 ± 14.9 51.7 ± 8.4a 168.2 ± 27.6b 113.4 ± 19.7abc 179.2 ± 16.2bd
SOD (U/mg protein) 34.1 ± 2.9 15.2 ± 1.3a 32.6 ± 2.6b 21.6 ± 2.1abc 31.3 ± 1.8bd
GPx (U/mg protein) 27.1 ± 1.0 19.3 ± 0.7a 26.8 ± 0.8b 23.4 ± 0.9abc 27.8 ± 1.1bd
GSH (lmol/g tissue) 13.6 ± 0.2 5.2 ± 0.1a 13.8 ± 0.4b 9.8 ± 0.1abc 13.2 ± 0.3bd
Data are expressed as mean ± SD (n¼ 6) and analysed by one-way ANOVA followed by Tukey post hoc test. Group 1: control group;
Group 2: diclofenac-alone treated group; Group 3: treated by diclofenac plus silymarin (100mg/kg p.o.); Groups 4 and 5 were treated
by diclofenac plus gallic acid (50, 100mg/kg p.o. respectively).
ap< 0.05 versus control group (Group 1),
bp< 0.05 versus diclofenac-alone treated group (Group 2),
cp< 0.05 versus group treated with silymarin (Group 3),
dp< 0.05 versus group treated with gallic acid at dose of 50mg/kg (Group 4).
Figure 1. Effect of gallic acid on serum interleukin 1 beta (IL-1b) and expression of IL-1b. Data are expressed as mean± SD (n¼ 6). Group 1: control group; Group 2:
diclofenac-alone treated group; Group 3: treated by diclofenac plus silymarin (50mg/kg p.o.); Groups 4 and 5 were treated by diclofenac plus gallic acid (50, 100mg/
kg p.o. respectively). ap< 0.05 versus control group (Group 1), bp< 0.05 versus diclofenac-alone treated group (Group 2), cp< 0.05 versus group treated with silymarin
(Group 3 ), dp< 0.05 versus group treated with gallic acid at dose of 50mg/kg (Group 4).
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accumulation of toxic metabolites in the liver. The liver toxicity
effects of diclofenac (DIC) in both animal models and humans
have been described (Bj€ornsson 2016; Licata 2016). Therefore,
discovery effective method for diminishing liver fibrosis and
inhibiting the progression of cirrhosis is very important.
One of the key markers of liver damage is the release of some
enzymes such as ALP, ALT, and AST into the circulatory blood
system. In this study significant increase observed in the levels of
ALT, AST, ALP, and total bilirubin content in DIC-only treated
animals in comparison with control animals confirmed the hep-
atotoxic potential of DIC (Table 1). This is in accordance with
prior studies showing an elevation in ALT, AST, ALP, and total
bilirubin levels in DIC-exposed humans and experimental ani-
mals (Adeyemi and Olayaki 2018; Alabi et al. 2017; Nouri et al.
2019). The diminution levels of total bilirubin, AST, ALT, and
ALP in gallic acid (GA) and silymarin treated groups suggested
that both components have protective effects against DIC-
induced hepatotoxicity. These findings are sustained by the prior
findings, which have indicated that GA attenuates selected drug
and chemical-induced hepatotoxicity (Karimi-Khouzani et al.
2017; Latief et al. 2016).
Malondialdehyde (MDA) level is a sign of lipid peroxidation
(LPO) (Gaweł et al. 2004). In the present study, the levels of
MDA were significantly increased in the DIC-alone adminis-
trated rats compared to the control group (Table 2), which is in
agreement with prior investigations (Alabi et al. 2017;
Ramezannezhad et al. 2019). In addition, the administration of
GA not only led to an increase in FRAP content in treated
groups compared to the DIC-alone treated group, but also let to
a decrease in MDA level in the serum and hepatic tissues (Table
2). The raised FRAP and declined LPO level in GA treated
groups might be due to its free radical scavenging property.
CAT and SOD are vital enzymes of the antioxidant defense
system. The SOD fuse two superoxide radicals (O2
) and cre-
ates H2O2. H2O2 is eventually transformed into H2O and oxygen
molecule by CAT in the peroxisomes (Sharifinasab et al. 2016;
Wei et al. 2014). Various investigations have indicated that DIC
could decline the actions of antioxidant enzymes in the liver
Figure 2. Effects of gallic acid on the liver histology of experimental groups. (A) Control group with normal structure; (B) diclofenac-alone treated rats; (C) diclofenac-
injected rats supplemented with silymarin (100mg/kg bw); (D) diclofenac-injected rats supplemented with gallic acid (50mg/kg bw); (E) diclofenac-injected rats sup-
plemented with gallic acid (100mg/kg bw). The black arrows show lymphocyte infiltration.
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(Ahmad et al. 2013; Nouri et al. 2019). GA as an antioxidant
agent could noticeably raise the activity of antioxidant enzymes
(Table 3). It confirms the prior findings that disclosed the anti-
oxidative potential of GA (Karimi-Khouzani et al. 2017; Latief
et al. 2016). The decline of SOD and CAT activities caused by
DIC injection was manifest by elevated oxidative stress.
However, GA treatment eventually reduced the MDA and ele-
vated the activities of antioxidant defense system enzymes in
hepatic tissue, reflecting its antioxidant potential mediated by
hepatoprotective activity.
In addition, the excessive production of ROS following DIC
exposure was related to the high levels of protein oxidation reac-
tion, leading to the formation of protein carbonyl (PC) levels,
signifying that oxidative protein damage might be one of the
mechanisms of DIC induced liver toxicity. These observations
are in line with previous investigations (Nouri and Heidarian
2019; Nouri et al. 2017). In the present study, the treatment with
GA prevented oxidative damage induced by DIC in the liver tis-
sue was along with a decrease in the level of PC (Table 3). In
fact, GA acts as a free radical scavenger and is able to stabilise
membrane structures.
Glutathione (GSH), an endogenous antioxidant, plays a main
role in cellular defense in damage caused by oxidative stress.
Both in vitro and in vivo reports have implicated the role of
GSH depletion in oxidative stress induced by DIC in different
model systems (Ahmad et al. 2013; Alabi et al. 2017; Niu et al.
2015). In the present study, DIC-induced liver toxicity caused a
remarkable elevation in the GSH content in liver tissues (Table
3) compared to the control group. On the other hand, a notice-
able restoration of GSH level observed in GA treated groups.
The restoration of GSH level induced by GA might be either due
to a direct increase in GSH content or due to decreased oxidative
stress.
In order to evaluate the effect of GA on GSH metabolism,
this study assessed its effect on GPx as GSH metabolising
enzyme. GPx simplifies the neutralisation of peroxides through
conjugation with GSH and leading to raised levels of oxidised
glutathione (GSSG), which is then reduced by GR back to the
sulfhydryl form (GSH) thus sustaining the antioxidant level.
DIC-induced variations in GPx activity have been described
prior to liver and kidney tissues (Ahmad et al. 2013; Peter et al.
2017). In the present study, DIC-induced reduction of GPx activ-
ity (Table 3) may be due to the defense mechanism against dim-
inution lipid peroxidation and a noticeable rise in GPx activity
in the administrated groups with GA can be due to the reduction
content of LPO or oxidative stress.
Some investigations have also shown that DIC can induce cir-
culation of macrophages and monocytes, which leads to the syn-
thesis and release of a variety of pro-inflammatory cytokines
including TNF-a and IL-1b (Peter et al. 2017; Nouri et al. 2019).
Many findings also revealed that IL-1b plays a vital role in the
maintenance and development of inflammation, and cytokines
elevation is associated with liver injury (Abd-Ellah 2016; Sultan
et al. 2017). The results of this research demonstrated that DIC
administration markedly upregulated the IL-1b expression in the
liver tissue (Figure 1). However, GA markedly decreased IL-1b
up-regulation. The results of this work noticed that GA could
ameliorate the liver injury caused by DIC via suppressing the
inflammatory response. When tissue damage happens, leucocytes
quickly migrate to sites of damage and initiate an inflammatory
response. Accordingly, the infiltration of leucocyte was consid-
ered a sign of inflammatory response (Laskin and Laskin 2001;
Pang et al. 2001). As already revealed in histopathological
findings, leukocyte infiltration was significantly elevated in the
liver of DIC-exposed rats. However, in our study treatment with
GA efficaciously reduced leucocyte infiltration in the liver of the
rats receiving DIC (Figure 2). Therefore, histopathological find-
ings indicated that GA could decrease the DIC-induced inflam-
matory response in the liver tissue.
Conclusions
The present study indicated that GA has ameliorative effects
against DIC-induced liver toxicity by reducing cellular ROS gen-
eration, restoring enzymatic and non-enzymatic antioxidants, as
well as improving liver function enzymes. Also, GA can amelior-
ate the abnormality of biochemical parameters and histopatho-
logical changes in DIC-induced liver toxicity.
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